CervoMed Stock Gets Higher EPS Estimate from HC Wainwright

CervoMed Inc. (NASDAQ:CRVO) – Equities research analysts at HC Wainwright increased their FY2026 earnings per share estimates for shares of CervoMed in a note issued to investors on Monday, November 9th. HC Wainwright analyst R. Selvaraju now expects that the company will earn ($2.25) per share for the year, up from their prior estimate of ($2.32). HC Wainwright currently has a “Buy” rating on the stock. The consensus estimate for CervoMed’s current full-year earnings is ($2.38) per share. HC Wainwright also issued estimates for CervoMed’s Q4 2026 earnings at ($0.50) EPS, Q1 2027 earnings at ($0.42) EPS, Q2 2027 earnings at ($0.35) EPS, Q3 2027 earnings at ($0.40) EPS, Q4 2027 earnings at ($0.44) EPS and FY2027 earnings at ($1.62) EPS.

CervoMed (NASDAQ:CRVO) last posted its earnings results on Monday, November 9th. The company reported ($0.39) EPS for the quarter, topping analysts’ consensus estimates of ($0.48) by $0.09.

Other equities analysts also recently issued reports about the stock. Roth Capital set a $7.00 target price on shares of CervoMed in a report on Thursday, August 20th. Chardan Capital raised shares of CervoMed to a “strong-buy” rating in a report on Monday, August 3rd. Wall Street Zen raised shares of CervoMed from a “strong sell” rating to a “sell” rating in a research note on Saturday, August 15th. Finally, Weiss Ratings downgraded CervoMed from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Thursday, September 3rd. One equities research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, CervoMed presently has an average rating of “Moderate Buy” and an average price target of $21.00.

CervoMed Stock Down 4.2%

NASDAQ:CRVO opened at $1.37 on Wednesday. CervoMed has a 52-week low of $1.27 and a 52-week high of $10.00. The stock has a fifty day simple moving average of $2.39 and a 200-day simple moving average of $3.35.

Hedge Funds Weigh In On CervoMed

Several institutional investors and hedge funds have recently modified their holdings of the company. Renaissance Technologies LLC acquired a new stake in CervoMed during the 1st quarter worth approximately $252,000. BlackRock Inc. acquired a new position in CervoMed during the 2nd quarter worth approximately $167,000. Byrne Asset Management LLC boosted its holdings in CervoMed by 248.6% in the 2nd quarter. Byrne Asset Management LLC now owns 51,250 shares of the company’s stock worth $159,000 after acquiring an additional 36,550 shares during the period. Citizens Financial Group Inc. RI purchased a new position in CervoMed in the 2nd quarter worth approximately $116,000. Finally, NFSG Corp boosted its holdings in CervoMed by 283.3% in the 3rd quarter. NFSG Corp now owns 11,500 shares of the company’s stock worth $34,000 after acquiring an additional 8,500 shares during the period. Hedge funds and other institutional investors own 25.15% of the company’s stock.

CervoMed Company Profile

CervoMed Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for neurodegenerative diseases. The company’s lead investigational product is neflamapimod, an orally administered, brain-penetrant small-molecule inhibitor of p38 alpha, an enzyme believed to play a role in neuroinflammation and cognitive decline. CervoMed is primarily evaluating neflamapimod as a potential treatment for dementia with Lewy bodies, a progressive neurological disorder associated with cognitive impairment, fluctuations in attention, visual hallucinations and movement symptoms.